Calibration of Five Different Thromboplastins, Using Fresh and Freeze-dried Plasma

D. R Bangham; R Biggs; M Brozović; K. W. E Denson

doi:10.1055/s-0038-1647766

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1973; 29(02): 228-239
DOI: 10.1055/s-0038-1647766

Original Article

Schattauer GmbH

Calibration of Five Different Thromboplastins, Using Fresh and Freeze-dried Plasma

D. R Bangham

¹Division of Biological Standards, National Institute for Medical Research, London, NW7 1AA, and the Haemophilia Centre, Medical Research Council Laboratory, Churchill Hospital, Oxford, England

,

R Biggs

¹Division of Biological Standards, National Institute for Medical Research, London, NW7 1AA, and the Haemophilia Centre, Medical Research Council Laboratory, Churchill Hospital, Oxford, England

,

M Brozović

¹Division of Biological Standards, National Institute for Medical Research, London, NW7 1AA, and the Haemophilia Centre, Medical Research Council Laboratory, Churchill Hospital, Oxford, England

,

K. W. E Denson

¹Division of Biological Standards, National Institute for Medical Research, London, NW7 1AA, and the Haemophilia Centre, Medical Research Council Laboratory, Churchill Hospital, Oxford, England

› Author Affiliations

Abstract

Summary

The results of this trial confirmed that the five different thromboplastin preparations could be calibrated in terms of thromboplastin 67/40 (2) in respect to their sensitivity to coumarin induced defect.

Using thromboplastin 2 (67/40) as reference and assigning to it, by definition, a TSR of 2.0, the other four thromboplastins can be assigned the following TSRs: thromboplastin 1 (69/223) 1.9: thromboplastin 3 (68/434) 2.0; thromboplastin 4 (70/115)2.0; and thromboplastin 5 (70/178) 1.5.

In view of the great amount of collaborative work which has been invested in the study of these preparations, they should be kept primarily for the purposes of calibrating other reference preparations rather than be consumed as working standards. Thromboplastin 67/40 should be preserved for calibrating future batches of an international reference material or of national reference preparations of a similar type. The other four preparations could be used to calibrate similar types of thromboplastin: human brain without added bovine factors (69/223) for calibration of similar human thromboplastins; the bovine thromboplastin (68/434) for bovine preparations, and the two different rabbit brain preparations (70/115) and (70/178) for calibration of the rabbit brain reagents. In this manner each of the preparations would be compared to a material of the same species and similar type, and the stocks of these materials conserved to last over a longer period of time.

Carefully prepared freeze-dried pooled plasma from patients on oral anticoagulants can be used instead of a large number of individual fresh plasmas to simplify the calibration procedure of selected thromboplastins.

In the present state of knowledge about the coumarin induced coagulation defect, artificially prepared abnormal plasmas appear to have little use in the calibration of thromboplastin preparations for control of anticoagulant therapy.

Full Text

References

References
1 Bangham D. R, Biggs R, Brozoviö M, Denson K. W. E. 1970. Draft report of a collaborative study of two thromboplastins (including the use of common abnormal plasma). In: Koller F, Brinkhous K. M, Biggs R, Rodman N. F, Hinnom S. (eds.), Vascular Factors and Thrombosis. F. K. Schattauer Verlag; Stuttgart - New York.:
2 Biggs R. 1965. Report on the standardization of one-stage prothrombin time for the control of anticoagulant therapy. In: Hunter R. B, Wright I. S, Koller F, Streuli F. (eds.), Genetics and the Interaction of Blood Clotting Factors. F. K. Schattauer Verlag; Stuttgart: 303.
3 Biggs R. 1969. The standardization of the prothrombin time for the control of anticoagulant therapy. In: Owren P. A, Brinkhous K. M, Pavlovsky A, Roberts H. R, Johnson A. J, Hinnom S. (eds.), Plasma Fractions for the Treatment of Hemophilia. Anticoagulant Therapy: Standardization of Tests. F. K. Schattauer Verlag; Stuttgart-New York: 87.
4 Biggs R, Bangham D. R. 1971; Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy: availability and use of thromboplastin reference preparations. British Medical Journal 02: 470.
5 Biggs R, Denson K. W. E. 1966. Second report on the standardization of the one-stage prothrombin time for the control of anticoagulant therapy. In Brinkhous K. M, Wright I. S, Koller F, Streuli F, Duckert F. (eds.), Diffuse Intravascular Clotting. F. K. Schattauer Verlag; Stuttgart: 345.
6 Biggs R, Denson K. W. E. 1967. Third report on the standardization of one-stage prothrombin time for the control of anticoagulant therapy. In: Brinkhous K. M, Wright I. S, Soulier J. P, Roberts H. R, Hinnom S. (eds.), Platelets: Their role in Hemostasis and Thrombosis. F. K. Schattauer Verlag; Stuttgart: 445.
7 Biggs R, Denson K. W. E. 1967; Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. British Medical Journal I: 84.
8 Brozović M, Gïïrd L. J, Robertson I, Bangham D. R. 1971; Factor X in freeze-dried Factor VIII reference plasma. British Journal of Haematology 21: 201.
9 Brozović M, Gurd L. J, Robertson I, Bangham D. R. 1971; Stability of prothrombin and factor VII in freeze-dried plasma. Journal of Clinical Pathology 24: 690.
10 Denson K. W. E. 1966. Criteria for a standard thromboplastin preparation. In Brinkhous K. M, Wright I. S, Koller F, Streuli F, Duckert F. (eds.), Diffuse Intravascular Clotting. F. K. Schattaner Verlag; Stuttgart: 363.
11 Denson K. W. E. 1967. Proposed specification for a reference thromboplastin preparation for the control of anticoagulant therapy using coumarin type drugs. In Brinkhous K. M, Wright I. S, Soulier JP, Roberts H. R, Hinnom S. (eds.), Platelets: Their role in Hemostasis and Thrombosis. F. K. Schattauer Verlag; Stuttgart: 437.
12 Denson K. W. E. 1969. Fourth report on the standardization of one-stage prothrombin time for the control of anticoagulant therapy. In: Owren P. A, Brinkhous K. M, Pavlovsky A, Roberts H. R, Johnson A. J, Hinnom S. (eds.), Plasma Fractions for the Treatment of Hemophilia. Anticoagulant Therapy: Standardization of Tests. F. K. Schattauer Verlag; Stuttgart-New York: 197.
13 Hemker H. C, Veltkamp J. J, Loeliger E. A. 1968; Kinetic aspect of the interaction of blood clotting enzymes : III. Demonstration of an inhibitor of prothrombin conversion in vitamin K. deficiency. Thrombosis et Diathesis Haemorrhagica 19: 346.
14 Loeliger E. A, Meuwisse-Braun J. B, Buitedijk F. J. J, Veltkemp J. J, Hemker H. C. 1970; Laboratory control of oral anticoagulants. Definition of therapeutic range in terms of different thromboplastin preparations. Thrombosis et Diathesis Haemorrhagica 23: 569.
15 Miale J. B, Lapond D. 1969; Prothrombin time Standardization. American Journal of Clinical Pathology 52: 154.
16 Poller L, Thomson J. M, Alderson M. R. 1971; The British system for anticoagulant control and thrombotest. Journal of Clinical Pathology 24: 143.
17 Poller L. 1971; Annotation : The British National Thromboplastin. British Journal of Haematology 20: 359.
18 Quick A. J. 1970; Thromboplastin as a reagent. Thrombosis et Diathesis Haemorrhagica 23: 585.
19 Zucker S, Cathey M, West B. 1970; Preparation of quality control specimens for coagulation. American Journal of Clinical Pathology 53: 924.